 SAN CARLOS, Calif., Dec. 07, 2021 GLOBE NEWSWIRE -- Iovance Biotherapeutics, Inc. NASDAQ: IOVA, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced participation in the following conferences in December: 